Eric L Garland1, Eron G Manusov2, Brett Froeliger3, Amber Kelly4, Jaclyn M Williams5, Matthew O Howard6. 1. College of Social Work. 2. Duke Southern Regional Area Health Education Center. 3. Department of Neuroscience. 4. School of Social Work, Smith College. 5. College of Social Work, Florida State University. 6. School of Social Work, University of North Carolina.
Abstract
OBJECTIVE:Opioid pharmacotherapy is now the leading treatment for chronic pain, a problem that affects nearly one third of the U.S. population. Given the dramatic rise in prescription opioid misuse and opioid-related mortality, novel behavioral interventions are needed. The purpose of this study was to conduct an early-stage randomized controlled trial of Mindfulness-Oriented Recovery Enhancement (MORE), a multimodal intervention designed to simultaneously target mechanisms underpinning chronic pain and opioid misuse. METHOD: Chronic pain patients (N = 115; mean age = 48 ± 14 years; 68% female) were randomized to 8 weeks of MORE or a support group (SG). Outcomes were measured at pre- and posttreatment, and at 3-month follow-up. The Brief Pain Inventory was used to assess changes in pain severity and interference. Changes in opioid use disorder status were measured by the Current Opioid Misuse Measure. Desire for opioids, stress, nonreactivity, reinterpretation of pain sensations, and reappraisal were also evaluated. RESULTS:MORE participants reported significantly greater reductions in pain severity (p = .038) and interference (p = .003) than SG participants, which were maintained by 3-month follow-up and mediated by increased nonreactivity and reinterpretation of pain sensations. Compared with SG participants, participants in MORE evidenced significantly less stress arousal (p = .034) and desire for opioids (p = .027), and were significantly more likely to no longer meet criteria for opioid use disorder immediately following treatment (p = .05); however, these effects were not sustained at follow-up. CONCLUSIONS: Findings demonstrate preliminary feasibility and efficacy of MORE as a treatment for co-occurring prescription opioid misuse and chronic pain. (PsycINFO Database Record (c) 2014 APA, all rights reserved).
RCT Entities:
OBJECTIVE: Opioid pharmacotherapy is now the leading treatment for chronic pain, a problem that affects nearly one third of the U.S. population. Given the dramatic rise in prescription opioid misuse and opioid-related mortality, novel behavioral interventions are needed. The purpose of this study was to conduct an early-stage randomized controlled trial of Mindfulness-Oriented Recovery Enhancement (MORE), a multimodal intervention designed to simultaneously target mechanisms underpinning chronic pain and opioid misuse. METHOD:Chronic painpatients (N = 115; mean age = 48 ± 14 years; 68% female) were randomized to 8 weeks of MORE or a support group (SG). Outcomes were measured at pre- and posttreatment, and at 3-month follow-up. The Brief Pain Inventory was used to assess changes in pain severity and interference. Changes in opioid use disorder status were measured by the Current Opioid Misuse Measure. Desire for opioids, stress, nonreactivity, reinterpretation of pain sensations, and reappraisal were also evaluated. RESULTS: MORE participants reported significantly greater reductions in pain severity (p = .038) and interference (p = .003) than SG participants, which were maintained by 3-month follow-up and mediated by increased nonreactivity and reinterpretation of pain sensations. Compared with SG participants, participants in MORE evidenced significantly less stress arousal (p = .034) and desire for opioids (p = .027), and were significantly more likely to no longer meet criteria for opioid use disorder immediately following treatment (p = .05); however, these effects were not sustained at follow-up. CONCLUSIONS: Findings demonstrate preliminary feasibility and efficacy of MORE as a treatment for co-occurring prescription opioid misuse and chronic pain. (PsycINFO Database Record (c) 2014 APA, all rights reserved).
Authors: Susan A Gaylord; Olafur S Palsson; Eric L Garland; Keturah R Faurot; Rebecca S Coble; J Douglas Mann; William Frey; Karyn Leniek; William E Whitehead Journal: Am J Gastroenterol Date: 2011-06-21 Impact factor: 10.864
Authors: Sarah Bowen; Neharika Chawla; Susan E Collins; Katie Witkiewitz; Sharon Hsu; Joel Grow; Seema Clifasefi; Michelle Garner; Anne Douglass; Mary E Larimer; Alan Marlatt Journal: Subst Abus Date: 2009 Oct-Dec Impact factor: 3.716
Authors: Mary Jo Larson; Michael Paasche-Orlow; Debbie M Cheng; Christine Lloyd-Travaglini; Richard Saitz; Jeffrey H Samet Journal: Addiction Date: 2007-05 Impact factor: 6.526
Authors: Kevin E Vowles; Katie Witkiewitz; Karen J Cusack; Wesley P Gilliam; Karen E Cardon; Sarah Bowen; Karlyn A Edwards; Mindy L McEntee; Robert W Bailey Journal: J Pain Date: 2019-11-21 Impact factor: 5.820
Authors: Wen Li; Eric L Garland; Patricia McGovern; Jennifer E O'Brien; Christine Tronnier; Matthew O Howard Journal: Psychol Addict Behav Date: 2017-04-24
Authors: Ryan C Shorey; Joanna Elmquist; Michael J Gawrysiak; Catherine Strauss; Ellen Haynes; Scott Anderson; Gregory L Stuart Journal: Subst Use Misuse Date: 2017-04-21 Impact factor: 2.164
Authors: Adrienne L Adler-Neal; Christian E Waugh; Eric L Garland; Hossam A Shaltout; Debra I Diz; Fadel Zeidan Journal: J Pain Date: 2019-08-01 Impact factor: 5.820